Form 4: Mural Oncology Director Benjamin Hickey Receives Significant Stock Option Grant

Mural Oncology plc's Director, Benjamin Hickey, was granted 8,637 stock options with an exercise price of $2.56, aligning his interests with the company's long-term performance.

Summary

• Benjamin Hickey, a Director of Mural Oncology plc (MURA), was granted 8,637 stock options on June 11, 2025.
• The exercise price for these options is $2.56 per share.
• The options will vest in full upon the earlier of the first anniversary of the grant date (June 11, 2026) or the date of the next Annual Meeting, contingent on Mr. Hickey's continued service with the Issuer.
• The stock options are for Ordinary Shares and have an expiration date of June 10, 2035.
• Following this transaction, Mr. Hickey beneficially owns 8,637 derivative securities directly.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive as the grant of stock options to a director is a standard practice that aligns the director's long-term interests with the company's performance and shareholder value, indicating continued commitment. It is not a major market-moving event but reflects stable corporate governance and compensation practices.

Positives

• The grant of stock options to Director Benjamin Hickey aligns his financial interests directly with the long-term performance and shareholder value of Mural Oncology plc.
• Equity-based compensation is a standard practice that incentivizes management and directors to contribute to the company's growth and success.

Future Outlook

The vesting schedule for the stock options, tied to continued service, indicates an expectation of Benjamin Hickey's ongoing commitment and contribution to Mural Oncology plc's future operations and strategic direction.

Management Comments

• "This option was granted on June 11, 2025. This option will vest in full upon the earlier of (i) the first anniversary of the date of the grant or (ii) the date of the next Annual Meeting, subject to the reporting person's continued service with the Issuer."

Industry Context

The grant of stock options to directors is a common and widely accepted practice across various industries, particularly in the biotechnology and pharmaceutical sectors where long-term value creation and retention of key talent are paramount. This aligns with typical compensation structures aimed at incentivizing leadership.

Comparison to Industry Standards

• The grant of stock options as a component of director compensation is a standard practice within the biotechnology and pharmaceutical industries, comparable to compensation strategies employed by companies like Moderna, BioNTech, or Gilead Sciences, which frequently utilize equity incentives to align director and executive interests with shareholder returns.
• The vesting conditions, tied to continued service and specific timeframes (one year or next annual meeting), are typical for such grants, ensuring retention and performance incentives.

Related Party Transactions

• The transaction involves the grant of stock options to Benjamin Hickey, a Director of Mural Oncology plc, which is a standard form of compensation for a related party.

Stakeholder Impact

• Shareholders: The grant aligns the director's interests with shareholder value, potentially leading to better long-term performance.
• Employees: While not directly impacting all employees, it reinforces a compensation structure that values long-term commitment and performance at the leadership level.

Next Steps

• The stock options will vest in full upon the earlier of June 11, 2026, or the date of the next Annual Meeting, subject to Benjamin Hickey's continued service.

Key Dates

Keywords

Mural Oncology, MURA, Stock Option, SEC Form 4, Insider Transaction, Director Compensation, Equity Grant, Beneficial Ownership